EF Hutton Initiates Coverage On Sernova with Buy Rating, Announces Price Target of C$5
EF Hutton analyst Tony Butler initiates coverage on Sernova (TSX:SVA) with a Buy rating and announces Price Target of C$5.
Sernova Receives Second Tranche Equity Investment From Evotec Of $6.8M At A Price Of $2.50/Share
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/ XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced that it has completed the second and final tranche of its previously